NCT06910384TerminatedPhase 2
A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)
An Open Label Study of STR04 in Participants With Amyotrophic Lateral Sclerosis
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.
- Status (registry)
- Terminated
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- First submitted
- 7 Mar 2025
- Start date
- 12 Aug 2025
- Primary completion date
- 16 Dec 2025
- Lead sponsor
- New England Cell Therapeutics, Inc.
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT06910384
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion:
- "Definite" or "Probable" ALS according to the Revised El Escorial criteria (Airlie House)
- ALS severity grade 1 or 2 according to the Japan ALS severity classification.
- ALSFRS-R scores of 2 or more for all items, with scores of 4 for all breathing- related items (i.e., dyspnea, orthopnea, respiratory insufficiency).
- Within 2 years of ALS onset.
- %FVC of 80% or more.
- Aged 18 to ≤75 years at the time of informed consent.
- Exclusion:
- Current Viral Infection (e.g. HBV, HCV, HIV, HTLV-1, HPVB19, syphilis, COVID- 19).
- Current low blood cell counts
- History of cancer, congenital malformations, or chromosomal abnormalities
- History of allergy to penicillin or streptomycin, or other serious allergies.
- Current poor medical condition, due to endocrine disease, metabolic disease, immune disease, blood disease, psychiatric disorders, neurological diseases, cardiovascular diseases, respiratory diseases, gastrointestinal diseases, musculoskeletal or connective tissue diseases, renal or urogenital diseases.
- History of intracranial lesions, or stenosis, dissection or severe atherosclerotic disease of a blood vessel in the head or neck.
- Current uncontrolled hypertension.
- Prior treatment with a cell or gene therapy.
- Currently participating in any other clinical trial.
- Women who are pregnant, breastfeeding, or plan to become pregnant during study participation
- Men with plan for their partner to become pregnant during study participation.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Neuromuscular Research Institute | Austin | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.